Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.08 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced in oligodendrocyte progenitor cells (4342 nCPM) | 1.00 |
| chemistry Open Targets | a small-molecule pocket | 0.60 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
Knock down and overexpress PCDH15 in oligodendrocytes; measure a transcriptome-wide state shift (bulk RNA-seq) and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- a transcriptome-wide state shift (bulk RNA-seq)
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves a transcriptome-wide state shift (bulk RNA-seq) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PCDH15 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: a transcriptome-wide state shift (bulk RNA-seq); α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PCDH15 in dopamine neurons, braak+0.21 (p 0.593) → +0.30 (p 0.436)receipt 3470
- PCDH15 in oligodendrocytes, braak-0.01 (p 0.982) → +0.04 (p 0.924)receipt 3469
Swarm cases
receipt 3470: PCDH15 in dopamine neurons, braak
- power
- full sample +0.40 (p 0.101, n 18), 95% CI -0.08 to +0.73. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.40 (p 0.101, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.42 (p 0.080, n 18). could be the mix.
- skeptic
- leave-one-out range +0.31 to +0.60, sign flips 0; without severely affected donors +0.40 (p 0.101, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCDH15 in dopamine neurons.
case closed: nothing better to follow up.
receipt 3469: PCDH15 in oligodendrocytes, braak
- power
- full sample -0.00 (p 0.990, n 18), 95% CI -0.47 to +0.46. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.01 (p 0.983, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.02 (p 0.928, n 18). could be the mix.
- skeptic
- leave-one-out range -0.09 to +0.14, sign flips 7; without severely affected donors -0.00 (p 0.990, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PCDH15 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts